Upstream Bio (UPB) Enterprise Value (2023 - 2026)

Upstream Bio's Enterprise Value history runs 4 years deep, the most recent figure standing at -$294.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 31.71% year-over-year to -$294.6 million in Q1 2026; TTM through Mar 2026 was -$294.6 million, a 31.71% increase from a year earlier, with the FY2025 full-year figure at -$341.5 million, up 27.41% from the prior year.
• Enterprise Value grew to -$294.6 million in Q1 2026 per UPB's latest filing, from -$341.5 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$31.5 million in Q1 2024 and bottomed at -$470.5 million in Q4 2024.
• The 4-year median for Enterprise Value is -$294.6 million (2026), against an average of -$251.0 million.
• Across the five-year window, Enterprise Value slumped 1269.03% in 2025 and jumped 31.71% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$109.8 million in 2023, then slumped by 328.42% to -$470.5 million in 2024, then climbed by 27.41% to -$341.5 million in 2025, then rose by 13.74% to -$294.6 million in 2026.
• Per Business Quant, the three latest UPB Enterprise Value figures stand at -$294.6 million (Q1 2026), -$341.5 million (Q4 2025), and -$372.4 million (Q3 2025).